Regulus Therapeutics Announces Results in Phase 1b Study for ADPKD Treatment
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced positive topline results from the third cohort of its Phase 1b study of RGLS8429 for ADPKD treatment. The study showed that RGLS8429 was well tolerated and demonstrated a dose response in reducing disease severity markers. Enrollment for the fourth cohort has begun, and the company plans to discuss a potentially pivotal Phase 2/3 study with the FDA.
June 24, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics announced positive results from its Phase 1b study of RGLS8429 for ADPKD treatment, showing safety and dose response. The company plans to discuss a Phase 2/3 study with the FDA.
The positive results from the Phase 1b study indicate that RGLS8429 is both safe and effective in reducing disease severity markers, which is likely to boost investor confidence. The upcoming discussions with the FDA for a Phase 2/3 study could further enhance the stock's outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100